COMMONWEALTH OF KENTUCKY CABINET FOR HEALTH AND FAMILY SERVICES DEPARTMENT FOR MEDICAID SERVICES

PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING

NOTE: This special called meeting will be held virtually via Zoom webinar.

Thursday, November 16th, 2023 1:00 P.M. to 4:00 P.M. (Eastern)

Access Information

Smartphone/Web	Dial-In
https://magellanhealth.zoom.us/s/99693210189	+1 312 626 6799 (US Toll) OR
Webinar ID: 996 9321 0189	+1 646 558 8656 (US Toll)
Password: 531498	Webinar ID: 996 9321 0189
	Password: 531498

AGENDA

- I. Call to Order and Welcome
- **II.** Executive Session (upon request)
- III. Old Business
 - a. Approval of November 2022 Meeting Minutes
 - b. Approval of March 2023 Meeting Minutes
 - c. Approval of May 2023 Meeting Minutes
 - d. Approval of September 2023 Meeting Minutes

IV. New Business

- a. New Products to Market to be reviewed as single products:
 - i. FilspariTM (Non-PDL Drug)
 - ii. Joenja® (Non-PDL Drug)
 - iii. MieboTM (Ophthalmic Immunomodulators)
 - iv. NgenlaTM (Growth Hormones)
 - v. OlpruvaTM (Non-PDL Drug)
 - vi. SkyclarysTM (Non-PDL Drug)
 - vii. VyjuvekTM (Non-PDL Drug)

V. Therapeutic Classes with Recommended Changes

- -Presented by Magellan Rx Management
 - a. Anti-Emetics/Anti-vertigo Agents, Other (Anti-Emetics: Other)
 - b. Cytokine and CAM Antagonists
 - c. Ophthalmic Antibiotics (Ophthalmic Quinolones)
 - d. Multiple Sclerosis Agents
- -Presented by MedImpact
 - a. Antipsychotics: Injectable
 - b. COPD Agents
 - c. Diabetes, GLP-1 Receptor Agonists
 - d. Glucagon Agents
 - e. Growth Hormones

- f. Immunomodulator, Atopic Dermatitis
- g. Multiple Sclerosis Agents
- h. Ophthalmic Immunomodulators

VI. Consent Agenda

- **a.** The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:
- Acne Agents, Oral
- Acne Agents, Topical
- Antibiotics, Topical
- Anticholinergics/Antispasmodics
- Antidiarrheals
- Antiemetics & Antivertigo Agents
 - o Oral Anti-Emetics: 5-HT3 Antagonists
 - o Oral Anti-Emetics: NK-1 Antagonists
 - o Oral Anti-Emetics: Δ-9-THC Derivatives
- Antifungals, Topical
- Antiparasitic, Topical
- Antipsoriatic, Oral
- Antipsoriatic, Topical
- Anti-Ulcer Protectants
- Antivirals, Topical
- Bile Salts
- GI Motility, Chronic
- Histamine II Receptor Blockers (H2 Receptor Antagonists)
- H. pylori Treatment
- Immunomodulators, Asthma
- Immunosuppressives, Oral (Immunosuppressants)
- Laxatives and Cathartics
- Ophthalmic, Allergic Conjunctivitis
 - o Ophthalmic Antihistamines
 - o Ophthalmic Mast Cells Stabilizers

- Ophthalmic, Antibiotics
 - o Ophthalmic Antibiotics, Non-Quinolones
- Ophthalmic, Antibiotics-Steroid Combinations
- Ophthalmic, Anti-inflammatories
 - Ophthalmic NSAIDs
 - o Ophthalmic Anti-inflammatory Steroids
- Ophthalmic, Antivirals
- Ophthalmic, Glaucoma Agents
 - Ophthalmic Beta Blockers
 - Ophthalmic Carbonic Anhydrase Inhibitors
 - o Ophthalmic Combinations for Glaucoma
 - o Ophthalmic Prostaglandin Agonists
 - Ophthalmic Sympathomimetics
 - o Ophthalmic Glaucoma Agents, Other
- Ophthalmic, Mydriatics & Mydriatic Combinations
- Ophthalmic Vasoconstrictors
- Otic Antibiotics
- Otic Anesthetic and Anti-Inflammatories
- Proton Pump Inhibitors
- Rosacea Agents, Topical
- Steroids, Topical
- Spinal Muscular Atrophy
- Ulcerative Colitis Agents

VII. Adjournment

- a. Schedule of Upcoming Meetings
 - i. January 18, 2024

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria please go to https://kyportal.magellanmedicaid.com/provider/public/home.xhtml.

PUBLIC SPEAKERS: If you would like to speak during the public session, please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at:

https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml.